(Reuters) – Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics’ executive Ankur Dhingra.
Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said.
Illumina has also reaffirmed its forecast for the first quarter and full-year 2024.
(Reporting by Pritam Biswas in Bengaluru; Editing by Shilpi Majumdar)
